Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 1.50% on September 22, with a trading volume of 1.263 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of September 19, 2024, the fund's latest share count was 8.17 billion shares, with a total size of 7.676 billion yuan, reflecting a year-to-date increase of 1966.38% in shares and 1931.78% in size compared to December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 87.92% during the management period [2] - The top holdings of the fund include Innovent Biologics (9.52%), WuXi Biologics (9.47%), BeiGene (8.73%), and others, with their respective market values and share counts detailed [2] - The cumulative trading amount over the last 20 trading days reached 37.235 billion yuan, with an average daily trading amount of 1.862 billion yuan [1][2]

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1][2]. Fund Performance - As of September 18, 2024, the fund's share volume reached 8.17 billion shares, with a total size of 7.839 billion yuan, reflecting an increase of 1966.38% in share volume and 1974.81% in size compared to its initial figures on December 31, 2023 [1]. - The fund manager, Ma Jun, has achieved a return of 90.14% since taking over management on January 3, 2024 [2]. Trading Activity - The ETF recorded a trading volume of 12.58 billion yuan on September 19, 2024, with an average daily trading amount of 18.71 billion yuan over the last 20 trading days [1]. - Year-to-date, the ETF has accumulated a total trading amount of 206.404 billion yuan over 176 trading days, averaging 11.73 billion yuan per day [1]. Top Holdings - The ETF's major holdings include: - Innovent Biologics (9.52% holding, 263 million yuan market value) - WuXi Biologics (9.47% holding, 258 million yuan market value) - BeiGene (8.73% holding, 238 million yuan market value) - CanSino Biologics (7.62% holding, 208 million yuan market value) - China National Pharmaceutical Group (7.17% holding, 196 million yuan market value) [2].

KPM HOLDING LIMITED 吉輝控股有限公司* (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 (stock code 股份代號: 8027) NOTIFICATION LETTER 通 知 信 函 Dear Non-registered Shareholder (Note 1), 19 September 2025 The following document(s) of KPM Holdings Limited ("Company") has/have been prepared in English and Chinese and is/are available on the websites of the Company at www.kpmholding.com and The Stock Exchange of Hong Kong Limited at www.hkexnews.hk (collectively "Websites"):- • Interim Report 202 ...

(stock code 股份代號: 8027) NOTIFICATION LETTER 通 知 信 函 Dear Shareholder(s), 19 September 2025 KPM HOLDING LIMITED 吉輝控股有限公司* (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) 吉輝控股有限公司 (「本公司」)下述文件已編制中、英文版本及於本公司之網站 www.kpmholding.com 香港聯合交易所有限公司之網站 www.hkexnews.hk (統稱「該等網站」)刊載:- • 2025 年中期報告 The following document(s) of KPM Holdings Limited ("Company") has/have been prepared in English and Chinese and is/are available on the websites of the Company at www.kpmholding.com and The Stock ...

2025 中期報告 1 吉輝控股有限公司 中期報告2025 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 的定位乃為相比其他在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資人士應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後 方作出投資決定。 由於GEM 上市公司一般為中小型公司，在GEM 買賣的證券可能會較於主板買賣的證券承 受較大的市場波動風險，同時無法保證在GEM 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 本報告乃遵照聯交所GEM 證券上市規則（「GEM 上市規則」）的規定而提供有關吉輝控股有 限公司（「本公司」）的資料。本公司各董事（「董事」）願共同及個別對本報告承擔全部責任。 各董事經作出一切合理查詢後確認，就彼等所深知及確信，本報告所載資料在所有重要方 面均屬準確及完整，不含誤導或欺騙成分，且並無遺漏其他事宜，以致令本報告內任何聲 明或本報告產生誤導。 本報告原文乃以英文 ...

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) experienced a decline of 3.38% on September 4, with a trading volume of 1.427 billion yuan. The fund has shown significant growth in both share volume and total assets since its inception in January 2024 [1][2]. Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159567) was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1]. - As of September 3, 2024, the fund's latest share volume was 6.668 billion shares, and its total assets reached 6.724 billion yuan. This represents an increase of 1586.48% in share volume and 1679.83% in total assets compared to December 31, 2023, when the share volume was 395 million shares and total assets were 378 million yuan [1]. Group 2: Trading Activity - Over the past 20 trading days, the cumulative trading amount for the Hong Kong Innovative Drug ETF (159567) was 33.138 billion yuan, with an average daily trading amount of 1.657 billion yuan. Since the beginning of the year, the cumulative trading amount over 165 trading days was 185.061 billion yuan, averaging 1.122 billion yuan per day [1]. Group 3: Fund Holdings - The current fund manager of the Hong Kong Innovative Drug ETF (159567) is Ma Jun, who has managed the fund since its inception, achieving a return of 99.52% during this period [2]. - Key holdings in the fund include: - Innovent Biologics (9.52% holding, 2.60 billion yuan market value) - WuXi Biologics (9.47% holding, 2.58 billion yuan market value) - BeiGene (8.73% holding, 2.38 billion yuan market value) - CanSino Biologics (7.62% holding, 2.08 billion yuan market value) - China National Pharmaceutical Group (7.17% holding, 1.96 billion yuan market value) - CSPC Pharmaceutical Group (6.34% holding, 1.73 billion yuan market value) - 3SBio (5.83% holding, 1.59 billion yuan market value) - Hansoh Pharmaceutical (4.54% holding, 1.24 billion yuan market value) - Zai Lab (2.86% holding, 781.055 million yuan market value) [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 吉輝控股有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08027 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,600,000,000 | HKD | | 0.03125 HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 1,600,000,000 | HKD | | 0.03125 HKD | | 50,000,000 | 本月底法定/註冊股本總額： HKD 50,000,000 FF301 第 1 ...

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.67% on September 1, with a trading volume of 1.985 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of August 29, 2024, the fund's latest share count was 6.686 billion, with a total size of 6.403 billion yuan, reflecting a year-to-date increase of 1591.03% in shares and 1594.74% in size compared to the end of 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 91.54% during the tenure [2] - The top holdings of the fund include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings in the portfolio [2] - The fund's liquidity is strong, with a cumulative trading amount of 34.181 billion yuan over the last 20 trading days, averaging 1.709 billion yuan per day [1]

吉辉控股(08027)发布2025年中期业绩，收入855.2万新加坡元，同比增加36.83%;期内利润113.3万新加坡 元，同比减少46.12%;每股基本盈利0.479新加坡分。 ...

截至2025年6月30日止六個月之中期業績公佈 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 KPM HOLDING LIMITED 吉輝控股有限公 司* （於開曼群島註冊成立的有限公司） （股份代號：8027） 吉輝控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及其 附屬公司截至2025年6月30日止六個月的未經審核業績。本公佈載有本公司2025年 中期報告全文，乃符合香港聯合交易所有限公司GEM證券上市規則有關中期業績 初步公佈附載資料的相關規定。 承董事會命 吉輝控股有限公司 主席 陳添吉 香港，2025年8月29日 於本公佈日期，執行董事為陳添吉先生及林欣慧女士，而獨立非執行董事為劉木 根先生、肖來文先生及陸翹彥先生。 本公佈的資料乃遵照《香港聯合交易所有限公司GEM 證券上市規則》而刊載，旨 在提供有關本公司的資料；各董事願就本公佈的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其所知及所信，本 ...